Azactam's ADD-Vantage
Executive Summary
Squibb announced an agreement under which the antibiotic Azactam (astreonam) "and possibly a number of other Squibb I.V. drugs" will be marketed in Abbott's ADD-Vantage system. Squibb's NDA for Azactam is pending.